Protocol Ledger

NCT04827576 · Phase II · TERMINATED

Study of Magrolimab in Patients With Solid Tumors

Interventional Phase II clinical trial protocol NCT04827576 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-01 Enrollment: 106 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04827576
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)106 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04827576
Protocol FieldVerified Registry Value
NCT IdentifierNCT04827576
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment106 participants (ACTUAL)
Registered Start Date2021-10-01
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04827576
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
University of Michigan Rogel Cancer CenterAnn Arbor, MIOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI